A5012668393- Long-Term Effects of COVID-19
- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- COVID-19 Clinical Research Studies
- Autopsy Techniques and Outcomes
- Autoimmune Neurological Disorders and Treatments
- Infectious Encephalopathies and Encephalitis
- Neurological disorders and treatments
- COVID-19 and Mental Health
- Retinal and Optic Conditions
- Palliative Care and End-of-Life Issues
- Leprosy Research and Treatment
- Polyomavirus and related diseases
- Neurofibromatosis and Schwannoma Cases
- Medicine and Dermatology Studies History
- Neurological Complications and Syndromes
- Developmental and Educational Neuropsychology
- Neuroscience, Education and Cognitive Function
- Neurological and metabolic disorders
- Takotsubo Cardiomyopathy and Associated Phenomena
- Vagus Nerve Stimulation Research
- Medical History and Innovations
- SARS-CoV-2 and COVID-19 Research
- interferon and immune responses
- NF-κB Signaling Pathways
Hospital Universitario HM Sanchinarro
2020-2024
Universidad San Pablo CEU
2024
Sociedad Española de Nefrología
2016-2020
University Hospital HM Puerta del Sur
2020
Hospital Virgen de la Luz
2016-2019
Medico
2016-2017
Hospital Universitario 12 De Octubre
2013-2016
Universidad Complutense de Madrid
2016
Spanish Multiple Sclerosis Network
2013
Research Institute Hospital 12 de Octubre
2011
<h3>Objective</h3> To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. <h3>Methods</h3> Retrospective multicenter registry patients MS suspected or confirmed diagnosis available disease course (mild = ambulatory; severe hospitalization; critical intensive care unit/death). Cases were analyzed for associations between identifying risk...
TRAIL and Receptor genes have been implicated in Multiple Sclerosis pathology as well the response to IFN beta therapy. The objective of our study was evaluate association these relation age at disease onset (AAO) clinical upon treatment Spanish MS patients. We carried out a candidate gene TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 TRAILR-4 genes. A total 54 SNPs were analysed 509 patients under treatment, an additional cohort 226 used validate results. Associations rs1047275 TRAILR-2 rs7011559...
The TNF-related apoptosis inducing ligand (TRAIL)/TRAIL receptor system participates in crucial steps immune cell activation or differentiation. It is able to inhibit proliferation and of T cells induce neurons oligodendrocytes, seems be implicated autoimmune diseases. Thus, TRAIL genes are potential candidates for involvement susceptibility multiple sclerosis (MS). To test whether single-nucleotide polymorphisms (SNPs) the human encoding TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 TRAILR-4...
Abstract Background This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) subcutaneous IFN β-1a during treatment titration in patients relapsing-remitting multiple sclerosis previously naïve β. Methods Eighty-four (66.3% females) were followed up 8 weeks, 25.3% overweight and 14.5% obese. Results Biomarkers steadily increased all period by 45.3% for β2-microglobulin, 262.8% olygoadenylate synthetase-1, 92.8% neopterin. Overall AE...
Introduction . Cognitive impairment (CI) affects 40–65% of patients with multiple sclerosis (MS). Few studies address telematic cognitive stimulation (TCS) in MS. The objective this study is to evaluate the efficacy and impact telestimulation or distance (TCS), without support face-to-face (FCS) Methods Multicentre, prospective, randomised, controlled study. We will include 98 MS EDSS ≤ 6, symbol digit modality test (SDMT) Pc 25, Multiple Sclerosis Neuropsychological Screening Questionnaire...
A relationship among April births, HLA-DRB1*15:01 genotype and risk of multiple sclerosis (MS) has been described. We aim to determine this association in our cohort Spanish MS patients.We genotyped allele 326 patients 226 controls (non-neurological disease patients) by SSP-PCR compared month birth with local births during the same period.MS carrying HLA-DRB1*15 were more frequently born December (10.3% HLA-DRB1*15+ vs. 3.8% HLA-DRB1*15-; p = 0.019). Controls less than non-carrier (0% 10.3%...